) The Mayo Clinic Scottsdale and the Mayo Hospital staff provide state-of-the-art outpatient and inpatient tertiary care for a regional, national, and international population of patients. The multi-disciplinary staff now number more than 260 physicians. Those physicians include multiple members who are dedicated to provide high quality cancer care for our patients. We are dedicated to the specific aims of the Scottsdale Community Clinical Oncology Program and we strive to: 1) reduce cancer patient morbidity and mortality, 2) provide access to NCI approved cancer control and prevention protocols, 3) provide a comprehensive cancer treatment program as part of a broad based national resource for the quality controlled distribution of investigational cancer treatments including new investigational anti-cancer agents, and 4) develop a basic science research base that will support translational collaboration and Mayo Scottsdale investigational protocol development. Currently our primary research base is the North Central Cancer Treatment Group (NCCTG) and additional research base memberships include the Eastern Cooperative Oncology Group (ECOG), the University of Rochester Cancer Center (URCC), and the National Surgical Adjuvant Breast and Bowel Project (NSABP). We also plan to join the Gynecologic Oncology Group (GOG) and we plan to fully participate in the Clinical Trials Study Unit (CTSU). We have in addition developed a contractual relationship with UCLA and we are active participants in the UCLA Cancer Treatment Network. Our relationship with UCLA along with several pharmaceutical contracts has allowed us to provide our patients with additional access to new and novel anti-cancer agents. We also remain specifically dedicated to our cancer control and prevention efforts through the NCCTG, NSABP, and URCC. The Mayo CCOP organization also provides cancer screening, prevention, and care through subspecialty clinics including the Breast Disease Center, Women?s Health, the Familial Cancer Program, and the Bone Marrow and Solid Organ Transplant Programs. Finally, the Mayo Scottsdale Board of Governors with the approval and support of the Mayo Foundation Executive Committee have declared that the care of the cancer patient and cancer research will be this institution?s major area of emphasis and growth over the next five to ten years. We are confident that we will meet and exceed the goals stipulated in this RFA.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Kelaghan, Joseph
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Arizona
United States
Zip Code
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Crozier, Jennifer A; Advani, Pooja P; LaPlant, Betsy et al. (2016) N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer 16:23-30
Galanis, Evanthia; Anderson, S Keith; Lafky, Jackie M et al. (2013) Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19:4816-23
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Atherton, Pamela J; Halyard, Michele Y; Sloan, Jeff A et al. (2013) Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer 21:1193-9
Barton, Debra L; Liu, Heshan; Dakhil, Shaker R et al. (2013) Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105:1230-8
Bolton, John S; O'Connell, Michael J; Mahoney, Michelle R et al. (2012) Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer 11:31-7
Laack, Nadia N; O'Neill, Brian Patrick; Ballman, Karla V et al. (2011) CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys 81:476-82
Moraska, Amanda R; Atherton, Pamela J; Szydlo, Daniel W et al. (2010) Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol 8:128-32
Chee, Cheng E; Jett, James R; Bernath Jr, Albert M et al. (2010) Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423. Cancer 116:2382-9

Showing the most recent 10 out of 97 publications